The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ragulin Iu.A.

Meditsinskiĭ radiologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossii, Obninsk

The combination of immunotherapy and radiation therapy for non-small cell lung cancer

Authors:

Ragulin Iu.A.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2018;7(5): 90‑96

DOI: 10.17116/onkolog2018705190

Read: 5044 times

Download PDF (RU)
Contact the author
Table of contents

THE COMBINATION OF IMMUNOTHERAPY AND RADIATION THERAPY FOR NON-SMALL CELL LUNG CANCER
THE COMBINATION OF IMMUNOTHERAPY AND RADIATION THERAPY FOR NON-SMALL CELL LUNG CANCER

To cite this article:

Ragulin IuA. The combination of immunotherapy and radiation therapy for non-small cell lung cancer. P.A. Herzen Journal of Oncology. 2018;7(5):90‑96. (In Russ.)
https://doi.org/10.17116/onkolog2018705190

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Resu­lts of combined treatment of patients with cere­bral gliomas. P.A. Herzen Journal of Onco­logy. 2024;(6):18-22
Anti­gen rece­ptors in the deve­lopment of CAR-T cells for glioblastoma immu­notherapy. P.A. Herzen Journal of Onco­logy. 2024;(6):91-95
Neoadjuvant drug therapy and onco­logical outcomes in patients with stage I–II breast cancer. P.A. Herzen Journal of Onco­logy. 2025;(1):5-12
The choice of radiotherapy dose fractionation regi­men for grade 4 gliomas depe­nding on the status of MGMT. P.A. Herzen Journal of Onco­logy. 2025;(1):13-18
The role of neoadjuvant chemotherapy in the combined treatment of loca­lly adva­nced non-small cell lung cancer and the prerequisites for a personalized approach to it. P.A. Herzen Journal of Onco­logy. 2025;(1):19-25
Local cyto­kine profile of the endo­metrium in patients with repeated implantation failures and its pharmacological correction by the secretome of peri­pheral blood mono­nuclear cells. Russian Journal of Human Reproduction. 2024;(5):46-54
Claudin-18.2 and gastric cancer: from physiology to carcinogenesis. Russian Journal of Archive of Pathology. 2024;(6):92-99
Mana­gement before anatomical lung rese­ctions: prehabilitation and functional testing. Piro­gov Russian Journal of Surgery. 2024;(12):91-98
Possibilities of using bacterial lysa­tes in the treatment and prevention of upper respiratory tract infe­ctious diseases. Russian Rhinology. 2024;(4):314-322
Prognostic factors and preoperative therapy in rese­ctable intrahepatic cholangiocarcinoma. Piro­gov Russian Journal of Surgery. 2025;(1):5-13
Abstract:

The review gives the data available in the literature on the treatment of non-small cell lung cancer by immunotherapy in combination with radiation therapy. It considers the possible mechanisms for strengthening the antitumor effects produced by a combination of radiation and immunotherapy, as well as the results of clinical trials dealing with this issue.

Keywords:

non-small cell lung cancer
radiation therapy
immunotherapy
combined treatment

Authors:

Ragulin Iu.A.

Meditsinskiĭ radiologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossii, Obninsk

Close metadata

References:

  1. Raprin AD, Starinskii VV, Petrova GV, eds. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2016. Moscow: MNIOI im. P.A. Gertsena — filial FGBU NMIRTs Minzdrava Rossii; 2017. (In Russ.)
  2. Butts C, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010;28(1):29-34. https://doi.org/10.1200/jco.2009.24.0333
  3. Pignon J, Tribodet H, Scagliotti G, Douillard J, Shepherd F, Stephens R, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552-3559. https://doi.org/10.1200/jco.2007.13.9030
  4. Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A, et al. Paclitaxel — carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-2550. https://doi.org/10.1056/nejmoa061884
  5. Hirsch F, Suda K, Wiens J, Bunn P. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016;388(10048):1012-1024. https://doi.org/10.1016/s0140-6736(16)31473-8
  6. Sacco P, Maione P, Rossi A, Bareschino M, Schettino C, Guida C, et al. Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer. Target Oncol. 2011;6(3):171-180. https://doi.org/10.2174/1574884711666161201123439
  7. Reck M, Rodríguez-Abreu D, Robinson A, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823-1883. https://doi.org/10.1056/nejmoa1606774
  8. Bremnes R, Busund L, Kilvær T, Andersen S, Richardsen E, Paulsen E, et al. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small-cell lung cancer. J Thorac Oncol. 2016;11(6):789-800. https://doi.org/10.1016/j.jtho.2016.01.015
  9. Brambilla E, Le Teuff G, Marguet S, Lantuejoul S, Dunant A, Graziano S, et al. Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer. J Clin Oncol. 2016;34(11):1223-1230. https://doi.org/10.1200/jco.2015.63.0970
  10. Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214-218. https://doi.org/10.1038/nature12213
  11. Garon E, Rizvi N, Hui R, Leighl N, Balmanoukian A, Eder J, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-2028. https://doi.org/10.1056/nejmoa1501824
  12. Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-1639. https://doi.org/10.1056/nejmoa1507643
  13. Brahmer J, Reckamp K, Baas P, Crinò L, Eberhardt W, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373(2):123-135. https://doi.org/10.1056/nejmoa1504627
  14. Herbst R, Baas P, Kim D, Felip E, Pérez-Gracia J, Han J, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-1550. https://doi.org/10.1016/s0140-6736(15)01281-7
  15. Lee Y, Auh S, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T-cells: changing strategies for cancer treatment. Blood. 2009;114(3):589-595. https://doi.org/10.1182/blood-2009-02-206870
  16. Demaria S, Kawashima N, Yang A, Devitt M, Babb J, Allison J, et al. Reduction of immature myeloid cells by treatment with all-trans-retinoic acid (ATRA) improves the immunotherapeutic effect of the combination of local radiation with CTLA-4 blockade. Int J Radiat Oncol Biol Phys. 2004;60(1:Suppl.):S175-S176. https://doi.org/10.1016/j.ijrobp.2004.06.102
  17. Zeng J, See A, Phallen J, Jackson C, Belcaid Z, Ruzevick J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343-349. https://doi.org/10.1016/j.ijrobp.2012.12.025
  18. Liang H, Deng L, Chmura S, Burnette B, Liadis N, Darga T, et al. Radiation-induced equilibrium is a balance between tumor cell proliferation and T-cell-mediated killing. J Immunol. 2013;190(11):5874-5881. https://doi.org/10.4049/jimmunol.1202612
  19. Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2014;3(4):345-355. https://doi.org/10.1158/2326-6066.cir-14-0196
  20. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687-695. https://doi.org/10.1172/jci67313
  21. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050-1059. https://doi.org/10.1038/nm1622
  22. Kalbasi A, Rengan R. Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. Transl Lung Cancer Res. 2007;6(2):169-177. https://doi.org/10.21037/tlcr.2017.03.03
  23. Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 2008;181(5):3099-3107. https://doi.org/10.4049/jimmunol.181.5.3099
  24. Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology. 2014;3:e28518. https://doi.org/10.4161/onci.28518
  25. Hanna GG, Illidge T. Radiotherapy and immunotherapy combinations in non-small cell lung cancer: a promising future? Clin Oncol. 2016;28(11):726-731. https://doi.org/10.1016/j.clon.2016.07.014
  26. Matsumura S, Demaria S. Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. Radiat Res. 2010;173(4):418-425. https://doi.org/10.1667/rr1860.1
  27. Kwilas AR. In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol.2012;2:104. https://doi.org/10.3389/fonc.2012.00104
  28. Janssens S, Tschopp J. Signals from within: the DNA-damage-induced NF-κB response. Cell Death Differ. 2006;13(5):773-784. https://doi.org/10.1038/sj.cdd.4401843
  29. Seifert L, Werba G, Tiwari S, Giao Ly NN, Nguy S, Alothman S, et al. Radiation therapy induces macrophages to suppress T-cell responses against pancreatic tumors in mice. Gastroenterology. 2016;150(7):1659-1672.e5. https://doi.org/10.1053/j.gastro.2016.02.070
  30. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD—L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687-695. https://doi.org/10.1172/jci67313
  31. Schaue D, Xie MW, Ratikan JA, McBride WH. Regulatory T cells in radiotherapeutic responses. Front Oncol. 2012;2:90. https://doi.org/10.3389/fonc.2012.00090
  32. Gong X, Li X, Jiang T, Xie H, Zhu Z, Zhou F, et al. Combined radiotherapy and anti-PD-L1 antibody synergistically enhances antitumor effect in non-small-cell lung cancer. J Thorac Oncol. 2017;12(7):1085-1097. https://doi.org/10.1016/j.jtho.2017.04.014
  33. Tokito T, Azuma K, Kawahara A, Ishii H, Yamada K, Matsuo N, et al. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small-cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer. 2016;55:7-14. https://doi.org/10.1016/j.ejca.2015.11.020
  34. Kanamori M, Nakatsukasa H, Okada M, Lu Q, Yoshimura A. Induced regulatory T-cells: their development, stability, and applications. Trends Immunol. 2016;37(11):803-811. https://doi.org/10.1016/j.it.2016.08.012
  35. Galgani M, De Rosa V, La Cava A, Matarese G. Role of Metabolism in the immunobiology of regulatory T-cells. J Immunol. 2016;197(7):2567-2575. https://doi.org/10.4049/jimmunol.1600242
  36. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253-268. https://doi.org/10.1038/nri3175
  37. Ehlers G, Fridman M. Abscopal effect of radiation in papillary adenocarcinoma. Br J Radiol. 1973;46(543):220-222. https://doi.org/10.1259/0007-1285-46-543-220
  38. Kalbasi A, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: a synergistic combination. J Clin Invest. 2013;123(7):2756-2763. https://doi.org/10.1172/jci69219
  39. Schaue D, McBride WH. Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol. 2015;12(9):527-540. https://doi.org/10.1038/nrclinonc.2015.120
  40. Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41(6):503-510. https://doi.org/10.1016/j.ctrv.2015.03.011
  41. Honeychurch J, Cheadle EJ, Dovedi SJ, Illidge TM. Immuno-regulatory antibodies for the treatment of cancer. Expert Opin Biol Ther. 2015;15(6):787-801. https://doi.org/10.1517/14712598.2015.1036737
  42. Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small-cell lung cancer. Cancer Immunol Res. 2013;1(6):365-372. https://doi.org/10.1158/2326-6066.cir-13-0115
  43. Formenti S, Golden E, Chachoua A, Pilones K, Demaria S. SP-0012: Abscopal responses in metastatic non-small-cell lung cancer (NSCLC): a phase II study of combined radiotherapy and ipilimumab. Radiother Oncol. 2017;123:S3-S4. https://doi.org/10.1016/s0167-8140(17)30456-5
  44. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919-1929. https://doi.org/10.1056/nejmoa1709937
  45. Hoopes DJ, Tann M, Fletcher JW, Forquer JA, Lin P-F, Lo SS, et al. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer. 2007;56(2):229-234. https://doi.org/10.1016/j.lungcan.2006.12.009
  46. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33(31):3541-3543. https://doi.org/10.1200/jco.2015.61.6870
  47. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz L, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143-e152. https://doi.org/10.1016/s1470-2045(17)30074-8
  48. Weller A, O’Brien MER, Ahmed M, Popat S, Bhosle J, McDonald F, et al. Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small-cell lung cancer. Eur J Cancer. 2016;59:65-78. https://doi.org/10.1016/j.ejca.2016.02.017
  49. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373-377. https://doi.org/10.1038/nature14292
  50. Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16(7):795-803. https://doi.org/10.1016/s1470-2045(15)00054-6
  51. Chen Y, Williams J, Ding I, Hernady E, Liu W, Smudzin T, et al. Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol. 2002;12(1):26-33. https://doi.org/10.1053/srao.2002.31360
  52. Nakayama Y, Makino S, Fukuda Y, Min K-Y, Shimizu A, Ohsawa N. Activation of lavage lymphocytes in lung injuries caused by radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys.1996;34(2):459-467. https://doi.org/10.1016/0360-3016(95)02101-9
  53. Zhao J, Ling L, Yorke ED, Milano MT, Liu W, Kavanagh B, et al. Simple Clinical Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy in Lung Cancer: A Pooled Analysis of 70 Studies. Int J Radiat Oncol Biol Phys. 2014;90(1):S60. https://doi.org/10.1016/j.ijrobp.2014.05.207
  54. Ahmed KA, Grass GD, Creelan B, Gray J, Kim S, Dilling TJ, et al. Tolerability and safety of thoracic radiation and immune checkpoint inhibitors among patients with lung cancer. Int J Radiat Oncol Biol Phys. 2017;98(1):224. https://doi.org/10.1016/j.ijrobp.2017.01.063
  55. Faivre-Finn C, Snee M. Traditional phase 1 and 2 studies in thoracic radiation oncology should be abandoned. Int J Radiat Oncol Biol Phys. 2014;90(3):487-489. https://doi.org/10.1016/j.ijrobp.2014.05.044
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.